Results 141 to 150 of about 56,399 (161)

Inhibition of mTOR down-regulates scavenger receptor, class B, type I (SR-BI) expression, reduces endothelial cell migration and impairs nitric oxide production.

Biochim Biophys Acta, 2014
Fruhwürth S, Krieger S, Winter K, Rosner M, Mikula M, Weichhart T, Bittman R, Hengstschläger M, Stangl H.   +8 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Breast Cancer Statistics, 2022

Ca-A Cancer Journal for Clinicians, 2022
Hyuna Sung, Kimberly D Miller, Rebecca L Siegel   +2 more
exaly  

Current treatment and recent progress in gastric cancer

Ca-A Cancer Journal for Clinicians, 2021
Smita S Joshi, Brian D Badgwell
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Critical care management of chimeric antigen receptor T‐cell therapy recipients

Ca-A Cancer Journal for Clinicians, 2022
Alexander Shimabukuro-Vornhagen, Boris Böll, Victoria Metaxa   +2 more
exaly  

A review of cancer immunotherapy toxicity

Ca-A Cancer Journal for Clinicians, 2020
Lucy Boyce Kennedy
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Cancer statistics, 2017

Ca-A Cancer Journal for Clinicians, 2017
Rebecca L Siegel, Kimberly D Miller
exaly  

Photodynamic therapy of cancer: An update

Ca-A Cancer Journal for Clinicians, 2011
Patrizia M Agostinis, Kristian Berg, Keith A Cengel   +2 more
exaly